
Philipp Harter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7019575/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1274-1284.	5.1	1,376
2	Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer, 2009, 115, 1234-1244.	2.0	1,270
3	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 852-861.	5.1	1,237
4	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2416-2428.	13.9	1,176
5	Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncology, The, 2016, 17, 1579-1589.	5.1	380
6	A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. New England Journal of Medicine, 2019, 380, 822-832.	13.9	373
7	Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Annals of Surgical Oncology, 2006, 13, 1702-1710.	0.7	367
8	Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. International Journal of Gynecological Cancer, 2011, 21, 289-295.	1.2	239
9	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 620-631.	5.1	215
10	Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecologic Oncology, 2011, 121, 615-619.	0.6	166
11	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. New England Journal of Medicine, 2021, 385, 2123-2131.	13.9	144
12	TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGOâ€OVAR) Tj ETQq	10 0 0 rgB ⁻	F/Qverlock 10
10	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian		105

13	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE, 2017, 12, e0186043.	1.1	105
14	LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial Journal of Clinical Oncology, 2017, 35, 5500-5500.	0.8	81
15	The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Current Opinion in Oncology, 2005, 17, 505-514.	1.1	58
16	Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer. Gynecologic Oncology, 2014, 135, 435-440.	0.6	57
17	BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecologic Oncology, 2016, 140, 443-449.	0.6	47
18	Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Review of Anticancer Therapy, 2010, 10, 81-88.	1.1	46

PHILIPP HARTER

#	Article	IF	CITATIONS
19	Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. Annals of Surgical Oncology, 2017, 24, 2720-2726.	0.7	44
20	Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al. International Journal of Gynecological Cancer, 2017, 27, 246-247.	1.2	44
21	Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5). Gynecologic Oncology, 2014, 133, 427-432.	0.6	40
22	Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy. Annals of Surgical Oncology, 2018, 25, 2053-2059.	0.7	36
23	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). Journal of Medical Genetics, 2019, 56, 574-580.	1.5	34
24	Bevacizumab in the Treatment of Ovarian Cancer. Advances in Therapy, 2012, 29, 723-735.	1.3	33
25	Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecologic Oncology, 2014, 132, 537-541.	0.6	32
26	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. Cancer Treatment Reviews, 2021, 99, 102255.	3.4	25
27	Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2016, 26, 1594-1600.	1.2	23
28	Prognostic Factors for Complete Debulking in First- and Second-Line Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, S14-S17.	1.2	21
29	Surgery for Relapsed Ovarian Cancer: When Should it Be Offered?. Current Oncology Reports, 2012, 14, 539-543.	1.8	20
30	Diagnosis of Li-Fraumeni Syndrome: Differentiating <i>TP53</i> germline mutations from clonal hematopoiesis. Human Mutation, 2018, 39, 2040-2046.	1.1	20
31	Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). Investigational New Drugs, 2013, 31, 1499-1504.	1.2	19
32	Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases. International Journal of Gynecological Cancer, 2017, 27, 444-451.	1.2	18
33	Clonal Hematopoiesis–Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. Journal of the National Cancer Institute, 2022, 114, 565-570.	3.0	17
34	Role of cytoreductive surgery in recurrent ovarian cancer. Expert Review of Anticancer Therapy, 2009, 9, 917-922.	1.1	12
35	Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). International Journal of Gynecological Cancer, 2020, 30, 1997-2001.	1.2	11
36	Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?. Cancers, 2021, 13, 5756.	1.7	11

PHILIPP HARTER

#	Article	IF	CITATIONS
37	Ovarian Cancer–Specific <i>BRCA</i> -like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. Clinical Cancer Research, 2021, 27, 6559-6569.	3.2	9
38	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer, 2021, 154, 190-200.	1.3	9
39	Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?. Geburtshilfe Und Frauenheilkunde, 2020, 80, 932-940.	0.8	7
40	A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer. Cancers, 2021, 13, 1764.	1.7	7
41	Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation – real life data. Gynecologic Oncology, 2021, 163, 569-577.	0.6	7
42	Is there a role for HIPEC in ovarian cancer?. Archives of Gynecology and Obstetrics, 2018, 298, 859-860.	0.8	6
43	Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. Journal of Gynecologic Oncology, 2021, 32, e82.	1.0	6
44	Early-stage epithelial ovarian cancer: is systematic lymph node staging mandatory?. Journal of Gynecologic Oncology, 2021, 32, e61.	1.0	5
45	Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring. Cancers, 2022, 14, 168.	1.7	5
46	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
47	In Reply: Response to Sammartino et al Current Oncology Reports, 2013, 15, 192-192.	1.8	0
48	A new standard of care or just another option for patients with relapsed ovarian cancer?. Lancet Oncology, The, 2017, 18, 701-702.	5.1	0
49	The role of factor XIII in surgery for advanced stage of epithelial ovarian cancer. Archives of Gynecology and Obstetrics, 2021, , 1.	0.8	0
50	Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation. International Journal of Gynecological Cancer, 2022, 32, 468-473.	1.2	0